Welcome to the Lisata Therapeutics First Quarter 2024 Financial Results and Business Update Conference Call. Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, John Menditto, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Thank you, operator, and good afternoon, everyone. Welcome to Lisata's First Quarter 2024 Conference Call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Chief Accounting Officer. Shortly before this call, a press release announcing our first quarter 2024 financial results was made available under the Investors and News section of the company website, along with the webcast replay of this call. If you have not received this news release or would like to be added to the company's e-mail distribution list, please email me at [email protected]. Before we begin, I remind you that comments made by management during this conference call may contain forward-looking statements involving risks and uncertainties regarding the operations and future results of Lisata. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-Q, 8-K, and 10-K which identify specific risk factors that may cause actual results to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, May 9, 2024. Lisata Therapeutics undertakes no obligations to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good afternoon, everyone. I'm delighted to be with you today to provide an overview of recent business highlights, discuss our first quarter 2024 financial results, and give an update on the progress of our various development programs. Building on the momentum of 2023, Lisata is off to a very strong start in 2024. We continue to make notable progress developing our lead product candidate, certepetide, formerly known as LSTA1, in combination with a variety of anticancer agents of different modalities as a treatment for multiple solid tumor cancers. As we have previously reported, encouraging preclinical data along with early clinical data in humans continue to support our belief that certepetide has the potential to become an integral part of a revised standard of care treatment approach for many challenging solid tumors. Dr. Kristen Buck, our Executive Vice President of Research and Development and Chief Medical Officer, will provide a detailed update of our ongoing and planned clinical programs following the financial results review. But before getting to the numbers, I want to mention the achievement of another important milestone for Lisata. Certepetide, spelled c-e-r-t-e-p-e-t-i-d-e, is the official international nonproprietary name, or INN, United States Adopted Name or USAN, and Australian Approved Name or AAN, now formerly assigned to LSTA1. Obtaining one of these names is part of the commercial development of a drug and represents an important step along the path to commercialization. Going forward, we will systematically use the name certepetide when referring to our product rather than the internal code of LSTA1 to emphasize the progress being made toward product registration.

Thanks, Dave. Good afternoon, all. I'm pleased to join you today to present a summary of our first quarter 2024 financial results. Starting with operating expenses. For the three months ended March 31, 2024, operating expenses totaled $6.6 million compared to $6.8 million for the three months ended March 31, 2023, representing a decrease of $0.2 million or 3.6%. Research and development expenses were approximately $3.2 million for the three months ended March 31, 2024, compared to $3.2 million for the three months ended March 31, 2023, representing an essentially unchanged spend. The minor increase of $62,000 or 2% was primarily due to an increase in expenses associated with our enrollment activities in the current year for our certepetide Phase 2a proof-of-concept BOLSTER trial, partially offset by a reduction in expenses associated with the Phase 2b ASCEND trial, which completed enrollment in the prior year. General and administrative expenses were approximately $3.4 million for the three months ended March 31, 2024, compared to $3.7 million for the three months ended March 31, 2023, representing a decrease of $0.3 million or 8.3%. This was primarily due to a decrease in staffing costs associated with the elimination of the Chief Business Officer position on May 1, 2023, a reduction in option assumption equity expense in connection with the Cend merger, a decrease in directors and officers insurance premiums, and a reduction in spending on consulting and legal fees, partially offset by one-off settlement-related costs. Overall, net losses were $5.4 million for the three months ended March 31, 2024, compared to $6.2 million for the three months ended March 31, 2023. Turning now to our balance sheet and cash flow. As of March 31, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $43.3 million. Based on our current business and development plans, the company believes that its available capital will fund operations into early 2026, encompassing anticipated data milestones from all its ongoing and currently planned clinical trials. This completes my financial overview, and I will now turn the call over to our Chief Medical Officer, Dr. Kristen Buck, for the review of our clinical development pipeline.

Thanks, James, and good afternoon, everyone. Lisata's development programs are based on sound scientific rationale from a vast body of published preclinical and early clinical works. These works include those that led to Dr. Erkki Ruoslahti being awarded the Lasker prize for the fundamental discoveries that spawned our CendR platform technology. A product of the CendR platform, certepetide is designed to address major impediments to the successful treatment of advanced solid tumors. This is especially relevant in an environment of increasing cancer prevalence and growing pharmacoeconomic pressures. Our clinical studies have been rigorously designed with the end in mind that is product registration, and they're optimized to generate clinically meaningful unambiguous data. As such, unlike many similarly phased studies, our studies are placebo-controlled, appropriately sized, and employ primary endpoints that are preferred by regulatory authorities in support of pivotal trials. Furthermore, our trials evaluate certepetide in combination with current standards of care to allow for clear discernment of treatment effect and to fit with current treatment practices at clinical sites. These strategic design choices are not always the least expensive approach, but they do afford us the most scientifically rigorous methodology by which to generate clinically meaningful data as efficiently and rapidly as possible. This is in keeping with our principle to do the last experiment first to avoid the time and capital consumption on work that could become unnecessary. We have also devised and implemented a regulatory strategy that optimizes certepetide's regulatory review and future commercialization. This strategy includes obtaining special regulatory designations, priority reviews, and accelerated approvals. I will speak more to the company's strategy in a moment. But as you can imagine, the aforementioned opportunities underpin why we are so excited about the initial top-line results that we'll report at the end of the year from our large Phase 2b ASCEND trial. However, before I get to the specifics of each of the clinical studies, allow me to provide some important background, especially for those who are listening to me for the first time. Despite advances in cancer therapy, including CAR-T cell therapy and immunotherapies, many solid tumors are still associated with poor outcomes for patients. Cancers, such as pancreatic cancer, gastric cancer, glioblastoma multiforme or brain cancer, and other solid tumors are surrounded by a dense fibrotic tissue known as the stroma, which actually limits access of most pharmacotherapies to the tumor. In addition, many solid tumors also present with a hostile tumor microenvironment, or TME, that suppresses a patient's immune system and makes it less effective in fighting cancer. The combination of the dense stroma and the hostile TME prevents many chemotherapies and immunotherapies from optimally being effective in treating these cancers. This, coupled with the fact that most anti-cancer therapies are not efficient in targeting only cancer tissue, defines the major challenge of maximizing effectiveness and safety in the treatment of solid tumors. However, to combat this, Lisata's approach is to exploit the CendR rule to activate the Cend active transport system. It's a naturally occurring active transport system to selectively deliver anticancer drugs through the stroma and into the tumor. Certepetide is a 9 amino acid cyclic peptide with high binding affinity and specificity for alpha v beta 3 and beta5 integrin receptors, which are significantly upregulated on tumor vascular endothelial cells and tumor cells but not healthy tissue. Once bound to these integrins, certepetide is cleaved by proteases naturally occurring in the tumor microenvironment. The proteases convert certepetide from a cyclic peptide into 2 linear peptides, one of which is a 5 amino acid CendR linear peptide fragment. Upon association of the CendR fragment from the integrin receptor, it binds to another receptor called neuropilin-1 on the same or nearby cell. Once neuropilin-1 is activated, it actuates the CendR-active transport mechanism, which is manifested by the formation of microvesicles at the surface of the cells. These microvesicles encapsulate moieties in the circulatory system, including any co-administered anticancer drugs, on certepetide and CendR fragments, and essentially ferries them through the stroma and vasculature into the tumor. Certepetide's mechanism of action is agnostic to the modality of the companion anticancer drug with which it's administered, and it can be combined with a wide range of existing or emerging anticancer therapies, including chemotherapies, immunotherapies, and RNA-based therapies. Additionally, as previously reported, certepetide has been shown in a range of preclinical models to modify the tumor microenvironment, making it less hostile to immune cells, reducing tumor resistance to anticancer medications, and actually impeding and preventing the metastatic cascade. These results come from Lisata sponsored studies and from collaborators and research groups around the world and have been the subject of more than 350 scientific publications relevant to certepetide's mechanism of action. Along with our collaborators, we've also amassed significant nonclinical data, demonstrating enhanced delivery of a range of anticancer therapy modalities, including chemotherapies, immunotherapies, RNA-based therapeutics, and even cell therapies. To date, certepetide has demonstrated favorable clinical safety, tolerability, and activity to enhance delivery of standard-of-care chemotherapy for patients with metastatic pancreatic cancer. As mentioned earlier, Lisata has worked diligently to optimize our regulatory strategy. The fruits of our labor can be seen in the number of special regulatory designations awarded to our product. For example, certepetide is the recipient of a fast-track designation by the FDA, which affords us more frequent interactions with the FDA and the ability to submit NDA components early for our rolling review. Certepetide will also be eligible for an accelerated approval and priority review if the relevant criteria are met. Furthermore, certepetide has received multiple orphan designations, including one for pancreatic cancer in both the U.S. and Europe as well as one for malignant glioma in the United States. Orphan designation affords Lisata exemption from user fees and provides extended market exclusivity. Since the start of 2024, certepetide has also received an orphan designation and a rare pediatric disease designation for osteosarcoma in the United States. Just for background, the FDA defines rare pediatric diseases as diseases with fewer than 200,000 cases in the U.S. that are serious or life-threatening and primarily affect individuals under 18 years of age. A substantial benefit of a rare pediatric disease designation is the receipt of a priority review voucher, often referred to as the golden ticket once the FDA approves a new drug application or NDA for the product and indication having received the designation. Vouchers are especially valuable as they can be used to compel a priority review of an additional NDA or biologic license application for another product or indication, reducing the standard review time of approximately 10 months to 6 months. The voucher may be used by a sponsor or sold to another sponsor for their use. Priority review vouchers have sold for as much as USD 350 million historically and more recently, have sold for between $75 million and $100 million. Overall, our development strategy includes the pursuit of a rapid certepetide registration for the treatment of metastatic pancreatic ductal adenocarcinoma alongside studies that further exploit certepetide's ability to enhance a variety of anticancer treatments in a range of solid tumors. To this end, certepetide is currently the subject of nearly a dozen planned or active clinical trials globally for the treatment of various solid tumors. For example, the ASCEND trial is a 158 patient double-blind, placebo-controlled randomized clinical trial, evaluating certepetide in combination with standard of care, gemcitabine, and nab-paclitaxel chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma, often known as mPDAC. The trial is being conducted at 25 sites in Australia and New Zealand, led by the Australasian Gastrointestinal Cancer Trials Group, or AGITG in collaboration with the NHMRC clinical trial center at the University of Sydney. The study consists of two cohorts. Cohort A received a single dose of 3.2 milligrams per kilogram of certepetide, essentially simultaneously with standard of care, while Cohort B is identical to Cohort A, but with the second dose of 3.2 milligrams per kilogram of certepetide given 4 hours after the first. As previously reported, a positive outcome from the planned interim futility analysis in 2023 was announced by the study's independent Data Safety Monitoring Committee, which recommended continuation of the study without modification. With trial enrollment completed in the fourth quarter of 2023, we expect top-line data from 95 patients assigned to Cohort A of the study to be reported in the fourth quarter of this year, and the complete data set of all 158 patients from the study to be available by mid-2025. The prospect of positive data is encouraging, and we have begun planning the subsequent development steps. For example, we've already received an opinion from the Therapeutic Goods Administration, or TGA, which is the medicine and therapeutic goods regulatory agency of the Australian government that they believe positive data from Cohort A of ASCEND warrant submission of an application for provisional determination, the Australian version of a conditional approval. We expect similar discussions with the FDA and EMA once the data are in hand. We have already anticipated and designed the required Phase 3 study that will be necessary to maintain the conditional approval and support full registration once completed. The ASCEND data anticipated this year will further inform and optimize our proposed Phase 3 clinical program in mPDAC. Next, the BOLSTER trial. The BOLSTER trial is our Phase 2a double-blind placebo-controlled multicenter randomized trial in the United States, evaluating certepetide in combination with standard of care in first-line cholangiocarcinoma. The BOLSTER trial was originally designed as a Phase 2, 3-arm basket trial, evaluating certepetide in combination with standards of care for second-line head and neck squamous cell carcinoma, second-line esophageal squamous cell carcinoma, and first-line cholangiocarcinoma. During months of study planning and initiation activities for the head and neck and esophageal cohort, however, we deemed that these two arms were not feasible to recruit given challenges with country-specific access to consistent standard of care drugs and delays in adding these standard of care drugs to national formularies. Given these obstacles, the two arms were going to take much longer to complete and be significantly more costly than originally projected. As a result, we took the fiscally responsible but nevertheless difficult decision to terminate these arms. Following that action, we strategically refocused the trial on the first-line cholangiocarcinoma arm. I'm actually delighted to report that Lisata's internal team has made significant enrollment progress to date that has far exceeded expectations. We expect to easily complete enrollment in first-line cholangiocarcinoma by the end of the year, if not substantially sooner. Also, the effectiveness of the sites involved in the first-line cholangiocarcinoma arm, along with the enthusiasm and efficiency of the corresponding investigators, has prompted us to consider initiating a BOLSTER study amendment for patients requiring second-line treatment for their cholangiocarcinoma. To achieve this, we are in active discussions with the FDA and our investigator network and we'll provide more news on this in the coming weeks and months. Next is the CENDIFOX study. It's a Phase 1b/2a open-label trial in the United States of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers, and it continues to make steady progress, with enrollment completion for all three arms expected by the end of this year 2024. This trial will provide us with pre- and post-treatment biopsy immuno-profiling data as well as long-term outcome data. Qilu Pharmaceutical, the licensee of certepetide in the Greater China territory, is also currently evaluating certepetide in combination with gemcitabine and nab-paclitaxel as a treatment for mPDAC. During the 2023 ASCO Annual Meeting, Qilu Pharmaceutical presented an abstract sharing preliminary data from the trial, which corroborated previously reported findings from the Phase 1b/2a trial of certepetide plus gemcitabine and nab-paclitaxel conducted in Australia in patients with metastatic pancreatic cancer. As recently announced, Qilu has begun treating patients in their Phase 2 placebo-controlled trial in mPDAC. The study is planned to take approximately 18 months to complete enrollment accrual and another 13 months for patient follow-up and data analysis and reporting. In collaboration with our funding partner, WARPNINE, the iLSTA trial is a Phase 1b/2a randomized, placebo-controlled, single-blind, single-center safety, early efficacy and pharmacodynamic trial in Australia. This three-cohort study is evaluating certepetide in combination with the checkpoint inhibitor durvalumab plus standard of care gemcitabine and nab-paclitaxel chemotherapy versus certepetide in combination with standard of care alone versus standard of care alone in patients with locally advanced non-resectable PDAC. Enrollment completion is expected in the second half of 2024. iGoLSTA, a Phase 1b/2a proof-of-concept safety and efficacy study, evaluating certepetide in combination with nivolumab and FOLFIRINOX as a first-line treatment in locally advanced non-resectable gastroesophageal adenocarcinoma is pending initiation as a function of the availability of funding by our partner, WARPNINE. The inspiration for this study comes from the findings recently published in the Oncology and Cancer Case Reports Journal, which details a patient with metastatic gastroesophageal adenocarcinoma who achieved a complete response when given certepetide in combination with standard of care FOLFIRINOX plus pembrolizumab. The subject initially underwent months of standard of care treatments and only achieved a partial response. Upon the subsequent addition of certepetide to the existing standard of care therapeutic regimen, the subject achieved a complete response confirmed both radiographically and surgically. Remarkably and thankfully, the subject remains healthy since achieving the complete response in February of 2023. We hope to provide an update on timing related to the execution of the iGoLSTA study in the coming quarters. A study of certepetide in combination with temozolomide in glioblastoma multiforme or GBM has been initiated with several patients already enrolled and treated. This study is designed as a Phase 2a double-blind placebo-controlled randomized proof-of-concept study evaluating certepetide when added to standard of care temozolomide versus temozolomide alone and matching certepetide placebo in patients with newly diagnosed glioblastoma multiforme. This actively enrolling study is being conducted across multiple sites in Estonia and Latvia and is targeted to enroll 30 patients with a randomization of 2:1, certepetide plus standard of care versus placebo plus standard of care. On top of the previously described studies, we're exploring additional trials supporting our general development strategy. However, we remain steadfast in only starting trials that can be funded through to data and trials that can be executed within a reasonable period of time. Finally, I would be remiss if I didn't remind you that several of the studies I mentioned are investigator-initiated trials. Although we have great confidence in our investigators running these studies, Lisata has limited control, and thus, timelines and expectations may be subject to change. That said, we are extremely grateful to the investigators and especially to the patients participating in certepetide clinical trials around the world. For those who are more interested, a more comprehensive description of each trial is available in the appendix section of the corporate presentation on our website. Additionally, in the body of the presentation, there are two slides that depict the anticipated timing and execution of key milestones and data readouts from our trials. As you will see, there are numerous execution and data milestones projected from our portfolio of clinical trials over the next year and beyond.

Can you hear me?

Yes.

Okay. I was having some technical difficulties. I apologize. Thank you, Kristen. We appreciate that comprehensive overview. Even with multiple data readouts over the next 18 months, as outlined by Kristen, we see the ASCEND initial top-line data as being seminal to the certepetide development program and to our company. These results will be instrumental in allowing us to consummate business transactions associated with the product and in defining our future capital needs. That said, we remain committed to advancing all of our certepetide development programs across a variety of solid tumor indications in order to fully exploit both the medical and commercial promise of certepetide. Now that we have entered the six-month window to data, our excitement and the attention we are receiving from prospective partners, licensors, and investors are increasing daily, and we look forward to sharing further details on our progress throughout the year. And with that overview, operator, we are ready to take questions.

Our first question comes from Joseph Pantginis from HC Wainwright.

This is Sara filling in for Joe. I wanted to ask, although it may be a bit premature, about certepetide and GBM. When do you expect to complete the target enrollment, and are you planning to share any preliminary data along the way, or will you wait until you have enrolled all 30 patients before looking at the data?

Thanks, I appreciate the question. I'm going to ask Kristen to jump in here in a minute on timing. But as it relates to taking a first look at data, this trial, like many of our other trials, is blinded and does not have a provision for an early breaking of the blind for an early look. So we'll have to wait until all 30 patients are actually enrolled and reached their end points. In terms of enrollment, Kristen can give you a better idea of what we're seeing right now, especially given that the trial had a safety observation period built in, which we're just coming to an end of and which will allow now for us to enroll patients at a much higher pace. So this is for the GBM trial in Estonia and Latvia.

Thanks, Sara, for the question. We have currently 3 subjects enrolled out of 30. And the last subject, I would say the first 3 subjects require a 30-day observation for safety. Our last subject of the 3 is 2 weeks into their 30-day safety running. To date, we've not seen any safety concerns. Therefore, within 2 or 3 weeks, we anticipate the rest of the enrollment to pick up.

Thank you. Our next question comes from Will Hidell from Brookline Capital Markets.

I had a quick question regarding the trial with Qilu. Why would they need 18 months to enroll the trial given your experience with ASCEND and I guess, the tendency for the Chinese oncology trials to enroll quickly?

Thanks, Will. I appreciate the question. To be clear, the Qilu trials are run exclusively by Qilu. All the operations and execution are completely within their purview. We do speak to them about strategy as part of the joint steering committee, but execution is completely up to them within China. I'm not sure that they will need 18 months, but that's what they had communicated publicly as their projection at the moment, and hopefully, they'll go faster.

It appears we're having technical difficulties with our operator to take the next question.

If someone has another question, can you just speak up? John, are you there? Can you see if we can get any response to figure out what's going on technically?

This is Pete Enderlin. Can you hear me?

Go ahead, Pete. Yes.

Okay, good. Well, the first question is just a technical financial question. You filed a $150 million shelf. I assume that's just to replace one that recently expired. But do you have anything further to say about the use of that other than obviously providing financial flexibility?

You answered your own question. That's really a housekeeping matter. Our previous shelf was expiring, and we always need to keep a shelf on trial in order to be able to take advantage of financing and other opportunities as they might arise. So right now, it's just financing housekeeping, if you will.

Okay. And then a more substantive question. For example, the BOLSTER trial is in the U.S., Europe, Canada, Australia and you have several trials that are in different venues around the world. So the question is, do those all operate, let's say, the one for the BOLSTER trial under U.S. FDA protocol or different standards in every country that you do them? And if that's true, why do you bother having all these different things to work under, which would make it more expensive and more complicated?

Thank you for the question. First, I want to clarify that in the pharmaceutical industry, when trials are conducted with international sites, they all adhere to the same protocol; otherwise, they would be treated as different trials. This consistency applies regardless of the enrollment location. We enroll internationally in certain studies to recruit patients more easily and to obtain a more diverse demographic, which is often necessary for later-stage studies. Currently, our BOLSTER trial is only being conducted in the United States, where we are enrolling patients with cholangiocarcinoma. We plan to conduct the second line study in the U.S. as well. Meanwhile, the ASCEND trial is taking place in Australia and New Zealand, and the GBM trial is being carried out in Estonia and Latvia. Additionally, some of our other trials are exploring sites worldwide. The main reasons for this global approach are to tap into patient prevalence and, in some cases, to achieve lower costs rather than higher ones, contrary to your assumption.

For example, with that trial in Estonia and Latvia, you would basically be discussing it with our FDA, even though it's being conducted over there?

Yes. At the European Union, the EMA as well.

Okay. But I'm not clear on who's actually setting the rules on what you have to do to run the trial. Is it the U.S. or Europe?

The protocol is set by us. The rules governing good clinical practice are actually set by the International Conference on Harmonization, to which the FDA, the EMA, the Japanese regulatory authorities, and myriad other regulatory authorities are signatories. So basically, there's a consistent international set of rules for conducting clinical trials, and that's what we will follow.

Our next question comes from Steve Brozak from WBB Securities.

I'm going to focus on the financial aspect. You've ensured that you have funding secured through 2026. You mentioned the possibility of obtaining a voucher after successfully completing the trial. However, I have a question regarding the patients you are treating, who are very ill. Ultimately, you will be handling patients who have undergone extensive and costly therapeutic treatments. Can you provide any insight into what these patients currently cost? I'm not asking for specific pricing on certepetide, but what is the system currently paying for the standard of care for these patients? Please focus on the United States, as costs vary by country. What are your thoughts on this? I have one follow-up question afterward.

Thanks for the question, Steve. I appreciate you being on. In the United States and in fact, in many other countries worldwide, the current standard of care for pancreatic cancer is chemotherapy. It falls pretty evenly distributed between two regimens. One is a combination of Gemcitabine and nab-paclitaxel. Nab-paclitaxel is also known as Abraxane. The other is FOLFIRINOX. These chemotherapeutics are actually generic right now and are covered by insurance generally for all these people. So I don't know the exact cost off the top of my head. But the fact is that the introduction of new therapies like immunotherapies, which are much more costly, is being readily absorbed by these patients because they have such dire circumstances and are seriously looking for other options. Typically, just to give you a ballpark, a typical regimen of gemcitabine and nab-paclitaxel is around $60,000. So that gives you some sense. Our product, as Kristen, I think, so eloquently described, is simply a small cyclic peptide. It's not as inexpensive to make as a small chemical entity, but it's made by solid-state chemistry that's pretty well standardized these days. Thus, it's expected to have a cost that will be very reasonable, especially in comparison to the cost of immunotherapies and some of the CAR-T cell therapies, which can cost hundreds of thousands of dollars or even millions of dollars. I hope that gives you a better idea.

That's exactly what I was looking for. You touched on the critical matter of all these immunotherapies that are out there and that are quite expensive and that are, frankly, not seeing the results that you're looking for. So if you're looking at that and because, unfortunately, you're seeing these patients who are so late-stage, especially in pancreatic cancer. I would imagine that this would be something you're looking at for positive results, but this would be looked at as something that is providing for a change of standard of care going forward. So going back to not just the benefit of a voucher, you're looking at a situation where you would actually be providing a quality care that is not seen today. Is that an accurate statement? Please fill in anything else, and I'll hop back in the queue.

No, Steve, I think that's accurate. In fact, what we see in some of our remarks and certainly in our press release, we expect that the addition of certepetide or its final approval will actually change the paradigm for standard of care, adding certepetide to current standards of care, which can evolve, should improve them regardless of what they are based on the mechanism of action that Kristen described. We really do see this as a paradigm changer for the treatment of solid tumor cancers and expect that it will have very broad applicability as a result.

Thank you all. Our next question comes from Robert Sassoon from Water Tower Research.

I was just wondering whether in the early studies that you've got a number of trials going on whether you've seen any variation in the performance of certepetide with respect to the various conditions that you're targeting.

Kristen, do you want to comment on that or please?

Sure. As Dave and I have mentioned before, safety has not been an issue. The drug's effectiveness usually depends on the anticancer agent it is combined with. Our trials are blinded, so I can't provide detailed insights, but I've received numerous calls from our investigators outside of work expressing their optimism about our drug's performance with cholangiocarcinoma patients. One investigator shared that a patient who was given just two weeks to live is now skiing three months later. While I can't definitively say if that's due to our drug, it's certainly where we've received the most positive anecdotal feedback.

Okay. And just one more question. Do you anticipate getting some milestone payments down the road? Do you have a sort of potential timeline for that?

We have an activity line, and the timeline is dependent on Qilu's execution. But we do have milestone payments that will be paid for the completion of activities, such as technology transfer for manufacturing and for initiating Phase 3 and ultimately, for registration. Now they've just started Phase 2, as we announced a couple of weeks ago, and we imagine it will take a while for them to get through Phase 2 and to get to Phase 3. But there's always the possibility that the results in China will be so good that they could convince the Chinese regulatory authorities that this Phase 2 trial could become the basis of a provisional application. Under those circumstances, that would qualify for the pivotal trial, and we could get a milestone along those lines as well. I can't really speak to timing, but certainly, over the course of the next several years, we would expect to collect some milestones from achievement.

Our next question comes from Robert LeBoyer from Noble Capital Markets.

I want to start by congratulating you on all the progress. In Dr. Buck's summary, I thought it was a very good and comprehensive overview. However, I missed whether the BOLSTER trial will be announcing data in 2025 or if there are any timelines for BOLSTER or CENDIFOX. I heard about the expected completion by the end of the year, but I didn't catch any details about the anticipated data release.

Thanks, Robert. Appreciate the question. Thanks for being on the call as well. All of our trials, as Kristen pointed out, are designed to reach data before our current cash outdate. So we're currently funded through early 2026, and everything is designed at this point in order to reach data before that. I would expect that with a BOLSTER trial, current target of approximately end of the year for completion of enrollment, we should certainly be announcing data before the end of the year next year. As Kristen pointed out, we could be completing enrollment in BOLSTER a lot sooner than that, which would just bring forward the data announcement to 2025.

I'm showing no further questions. This concludes the question-and-answer session. I will now turn it back over to Dr. Mazzo for closing remarks.

Thank you, operator. And again, thank you all for participating in today's call. We look forward to speaking with you again during our next quarterly conference call and to continuing to provide updates on our achievements and progress. We remain grateful for your continued interest and support. Stay well, and have a good evening.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.